

# Immunotherapeutics Committee

## Leadership

Co-Chairs: ..... Siwen Hu-Lieskovan, MD, PhD  
 ..... Katerina Politi, PhD  
 Executive Officer: ..... Gary H. Lyman, MD  
 Protocol Project Manager: ..... Christopher Kippola  
 Clinical Trial Program Manager: ..... TBD

## Time/Location

Wednesday, October 19, 2022 4:30 pm - 6:30 pm  
 Room: Regency B (Ballroom Level, West Tower)

## Agenda

- |                       |   |
|-----------------------|---|
| <b>4:30 - 5:00 pm</b> | <b>S2101 – iMATCH Pilot (BICAZO) kick-off</b><br>Katerina Politi, Siwen Hu-Lieskovan, Paul Swiecicki,<br>Michael LeBlanc, Katherine Minichiello, Dana Sparks,<br>Chris Kippola, James Moon, Gary Lyman, and the SWOG<br>iMATCH team   |
| <b>5:00-5:10 pm</b>   | <b>Q &amp; A</b>  |
| <b>5:10-5:40 pm</b>   | <b>Computational modeling of response to immune<br/>Checkpoint inhibitors</b><br>Shirley Liu, PhD<br>Founder and CEO, GV20 Therapeutics<br>Previously Professor of Biostatistics and Computational<br>Biology at Dana-Farber Cancer Institute, Harvard T.H.<br>Chan School of Public Health |
| <b>5:40-5:50 pm</b>   | <b>Q &amp; A</b>  |
| <b>5:50-6:20 pm</b>   | <b>Single-cell based immune-monitoring for IO clinical<br/>trials</b><br>Sean Bendall, PhD<br>Associate Professor of Pathology at Stanford University   |
| <b>6:20-6:30 pm</b>   | <b>Q &amp; A</b>  |

## Developing Studies

**S2101**, Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study. Dr. Hu-Lieskovan.